Open AccessAutologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial
Author(s) -
N. Ahmed,
V. Brawley,
M. Hegde,
K. Bielamowicz,
A. Wakefield,
Azam Ghazi,
A. Ashoori,
O. Diouf,
C. Gerken,
D. Landi,
M. Kalra,
Zhengjun Yi,
C. Rooney,
G. Dotti,
A. Gee,
H. Heslop,
S. Gottschalk,
S. Powell,
R. Grossman,
W. Wels,
Y. Kew,
D. Baskin,
J. Zhang,
P. New,
J. Hicks
Publication year - 2015
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/3ep7-r524
Subject(s) - bispecific antibody , glioblastoma , medicine , clinical trial , cancer research , oncology , immunology , antibody , monoclonal antibody
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom